45 results about "Antidepressant" patented technology

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an adenosine A2a / A2b receptor dual antagonist in preparation of an anti-depression medicine and a medicine for preventing or treating depression. The invention provides a new application of the adenosine A2aR / A2bR double antagonist, animal experiments prove that the adenosine A2aR / A2bR double antagonist AB928 can effectively treat depression of mice, does not have obvious toxic or side effects, increases indications of the AB928, and has a prospect of being applied as an anti-depression drug in practice, so that the medical application of the adenosine A2aR / A2bR double antagonist AB928 is further expanded.

Dosage forms, drug delivery systems, and methods related to dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The invention discloses a lactobacillus paracasei MLL28 strain and application thereof in resisting depression and inflammation, and belongs to the technical field of biomedicine. The strain is preserved in the China General Microbiological Culture Collection Center, called CGMCC for short, the preservation address is Institute of Microbiology, Chinese Academy of Sciences, No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing, the preservation number is CGMCC No.37583, the preservation date is January 30, 2026, and the taxonomic name is Lactobacillus paracasei. The strain provided by the invention has good tolerance to gastrointestinal tract environment, can significantly improve depression-like behaviors and regulate the levels of neurotrophic factors, neurotransmitters and inflammation-related factors, has good anti-depression and anti-inflammatory effects, and can provide a new technical approach for emotion regulation, depression state improvement and anti-inflammation.

The invention relates to the technical field of biomedicine and pharmacy, and discloses application of polypeptide in preparation of a medicine for treating and / or preventing depression. An IL-33 / ST2 signal channel in an LS brain region is a key endogenous protection mechanism for maintaining normal emotion, and by constructing a CSDS depression mouse model for verification, the 81st-95th amino acid sequence of the IL-33 protein is determined to be a core active fragment of the IL-33 protein combined with an ST2 receptor and exerting an anti-depression function. Experiments prove that no matter through intraperitoneal injection or LS brain region local injection, the polypeptide can significantly improve mouse depression-like behaviors induced by a CSDS or LPS model. The polypeptide provided by the invention is small in molecular weight, can pass through a blood brain barrier after being fused with TAT, and provides important candidate molecules and treatment strategies for developing novel and effective antidepressant drugs.

The invention relates to a composition comprising a piperazine-benzazepine, a buffer and a surfactant, and uses of such compositions such as treating, preventing, and / or suppressing symptoms of schizophrenia, schizoaffective disorders, and / or Parkinson's disease. The compositions have improved parameters such as a lower variance in pH, improved stability during storage, and lower solubility of piperazine-benzazepines, resulting in piperazine-benzazepine particle formation with improved particle size and particle size distribution. The compositions are useful as therapeutic agent, for instance through parenteral administration to a subject.

The application belongs to the technical field of medicines, and specifically discloses an anti-depression m-hydroxybenzoic acid compound and a preparation method and application thereof; the m-hydroxybenzoic acid compound Hyperioxides A-F provided by the application has not been reported; the six compounds have good anti-depression effects, and further research shows that the compounds Hyperioxide A, Hyperioxide D, Hyperioxide E and Hyperioxide F have significant protective effects on SH-SY5Y cells induced by corticosterone, and are superior to positive drugs fluoxetine and Luoyoutei, and can be used for developing drugs for treating depression.

The invention relates to (i) the prevention or treatment of a sleep disturbance, preferably in a patient having neuropathic pain; and / or (ii) the prevention or treatment of neuropathic pain in a patient having a sleep disturbance; and / or (iii) the prevention or treatment of neuropathic pain in a patient having been treated previously and / or being treated concomitantly with an analgesic medication for relief of neuropathic pain, preferably selected from antiepileptics, antidepressants and opioid analgesics, wherein the patient preferably has a sleep disturbance; in either cases by means of one or more high-concentration capsaicin and / or capsaicinoid topical dose units, preferably pharmaceutical patches, comprising capsaicin and / or capsaicinoid at a concentration of at least 2.5 wt.-%, relative to the total weight of dose unit.

The application discloses an IGFBP-2 derived polypeptide and application thereof in preparation of an antidepressant, and relates to the technical field of biological medicines. The amino acid sequence of the polypeptide is Pro-Lys-Lys-Leu-Arg-Pro, the N terminal of which is acetylated and the C terminal of which is amidated, and the amino acid sequence is shown as SEQ ID NO:1. The polypeptide has a small molecular weight, can easily penetrate the blood-brain barrier, and has good stability after terminal modification. Animal experiments prove that the polypeptide can significantly improve the depressive behavior of Shank3 gene knockout mice, including improving the spatial cognitive ability, enhancing the social interaction and curiosity, and relieving the anxiety behavior. Cell experiments prove that the polypeptide can significantly improve the viability of hippocampal neuron cells from Shank3 gene knockout mice, and up-regulate the expression level of synaptic plasticity related proteins GluA1 and SYN1. The polypeptide can be prepared by a chemical synthesis method, has low cost, and can be used for preparing a medicine for preventing or treating depression (especially depression related to Shank3 gene mutation).

The present application relates to the field of biological science, and particularly relates to the use of a SCN11A protein detection reagent in the preparation of a depression screening and depression treatment effect evaluation kit. It is found for the first time that the expression level of SCN11A protein in the peripheral blood serum of a depression patient is significantly higher than that of a healthy subject. The reagent for detecting SCN11A protein is used in the preparation of a depression screening kit, so that effective screening of depression and evaluation of the treatment effect of depression can be realized.

The invention relates to the technical field of medicines, and particularly provides application of a 6-(substituted pyridine-4-yl)-5-(substituted phenyl)-1, 2, 4-triazine compound derivative in preparation of an antidepressant drug. A cell experiment proves that the 6-(substituted pyridine-4-yl)-5-(substituted phenyl)-1, 2, 4-triazine compound is an antagonist of an adenosine 2A receptor, and a plurality of animal model experiments prove that the 6-(substituted pyridine-4-yl)-5-(substituted phenyl)-1, 2, 4-triazine compound has a relatively good treatment effect on a plurality of depression models. The compound has an application prospect of being used as an anti-depression treatment drug.

The invention belongs to the technical field of medicines, and particularly discloses a novel tricyclic alpha acid compound as well as a preparation method and application thereof. According to the present invention, the novel tricyclic alpha acid compounds (+ / -)-Humulunes M-O and (-)-Garcinielliptone HE have not been reported at present; the compound has a remarkable protection effect on HT22 cells induced by corticosterone and SH-SY5Y cells induced by LPS (Lipopolysaccharide), and can be used for developing medicines for treating depression.

The present invention relates to the field of pharmacy, and in particular to compounds of formula (I) as pharmaceutically active compounds. Compounds of formula (I) have been proven for the first time to be particularly useful for the treatment of depression and eating disorders related to depression, or diseases with depressive pathology as well as for the treatment of appetite related side effects of antidepressants and antipsychotics.

Disclosed are a benzothiazepine compound, a preparation method therefor, and use thereof. Specifically disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound or the salt thereof has one or more of the following advantages: selective inhibition of HDAC6, stable metabolism, low toxicity, inhibition of tumor cells, protection of nerve cells, and having a relatively good in vivo antidepressant effect, and is expected to be used as a novel therapeutic agent for the clinical treatment of cancer or diseases of the nervous system.

The present invention relates to 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use in treating a patient who has been diagnosed with a mental disorder or a nervous system disorder by administration of a 5-MeO-DMT / salt treatment course. The 5-MeO-DMT / salt treatment course involves administration of one or more doses of 5-MeO-DMT or a pharmaceutically acceptable salt thereof on a single day to remove or alleviate one or more symptoms of the mental disorder or the nervous system disorder. The patient is also treated with one or more antidepressant(s).

A system for remotely determining the potential presence of depression in a user. The system includes a virtual agent that administers one or more tasks to the user. The user performs the tasks and the performance is captured by a camera. The captured audiovisual data is sent to a server that derives objective metrics which are then applied to a classifying algorithm. If certain metrics meet certain thresholds, the system determines that the user is exhibiting depression symptoms. In embodiments, the system can further determine whether a user has been taking depression medication.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The invention belongs to the technical field of biological medicines, and discloses application of an RyR2 inhibitor in preparation of an anti-depression medicine and application of RyR2 in preparation of a depression diagnosis product. Experiments show that RyR2 not only can be used as a biomarker for diagnosing depression, but also can be used as an important target for developing drugs for treating / preventing depression. In addition, the invention further indicates that the RyR2 inhibitor TMDJ-035 has a rapid anti-depression effect and can be used for treating / preventing depression.

The present disclosure is directed to kappa opioid receptor ligands and pharmaceutical compositions thereof and their utility as neurological modulators (e.g., anti-nociceptive agents, antidepressants, anxiolytics, antipruritics). Specifically, the disclosed kappa opioid ligands are G-protein biased kappa opioid agonists containing a core and three different arms as is shown in Formula (A) below.

This invention relates to the field of traditional Chinese medicine (TCM) technology, and particularly to a TCM composition for treating tinnitus. Its ingredients include: vinegar-processed turtle shell, stir-fried jujube seed, anemarrhena rhizome, phellodendron bark, rehmannia root, white peony root, poria cocos, fleeceflower root vine, scutellaria barbata, oldenlandia diffusa, stir-fried atractylodes macrocephala, prunella vulgaris, and cicada slough. The TCM composition of this invention exhibits significant multi-dimensional beneficial effects in treating tinnitus. Compared with Western medicine treatments, it avoids the side effects such as low blood pressure, dizziness, drowsiness, and dry mouth associated with vasodilators and antidepressants, and overcomes the drawbacks of physical therapy, which only temporarily relieves symptoms and cannot cure the condition. It has the advantages of holistic conditioning and fewer side effects, providing a safe, effective, and comprehensive treatment plan for tinnitus patients, and has high clinical application value and promotional significance.

The present application provides a preparation method of ganoderma triterpene and its application in preparing an antidepressant, the prepared ganoderma triterpene has clear material basis, stable component composition and controllable preparation process, the ganoderma triterpene can improve stress-induced abnormal behavior, protect hippocampus and intestinal tissue structure, regulate inflammatory response, neuroendocrine function and various neurotransmitter homeostasis, and realize the synergistic regulation of the intestinal-brain axis function by regulating the intestinal flora structure and its metabolites. The present application provides an implementable technical solution for the application of ganoderma triterpene in functional food or natural antidepressant preparation.

The present invention concerns formulations of adrenalin with an antidepressant and N-acetylcysteine or a derivative thereof, providing higher exposure to adrenalin, and exhibiting improved stability, and their use for the treatment of shocks.

This invention discloses a method for preparing anthocyanin-coated nanoparticles and their applications. First, anthocyanins and extracellular vesicles (EVs) are extracted from honeysuckle fruit to obtain anthocyanin powder. Then, PBS and squalene are added to the anthocyanin powder to obtain squalene@anthocyanin. Next, EVs are added to squalene@anthocyanin, co-incubated, and then centrifuged to obtain anthocyanin-coated nanoparticles. These nanoparticles have a particle size of 180-220 nm, a zeta potential of -45 to -55 mV, and an encapsulation efficiency ≥85%. They exhibit excellent stability and biocompatibility, possessing functions such as regulating gut microbiota, antidepressant, antioxidant, and anti-inflammatory effects. Furthermore, their good biocompatibility and low toxicity solve the problems of stability and bioavailability, achieving precise regulation of gut microbiota and providing a safe and efficient new approach for the treatment of depression.

Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.

The application discloses a kind of inhibitors of targeting 5-HTT / HDAC double target and preparation method and application thereof.The application is based on the principle of rational drug design, and synthesizes novel small-molecule compounds with 5-HTT and HDAC inhibitory activity, multi-targets with potential antidepressant activity.The inhibitors of targeting 5-HTT / HDAC double target have both 5-HTT inhibitor effect and HDAC inhibitory effect, and are a kind of multi-target fluoxetine derivatives with 5-HTT and HDAC synergistically realizing antidepressant.The compound of the application is superior to fluoxetine compound in design strategy, introduces isoxazoles structure that can improve antidepressant activity, improves antidepressant activity, and has good improvement on the shortcomings of long treatment time and large side effects of currently used antidepressant compounds.

This invention relates to the field of plant-derived extracellular vesicles, and discloses a method for preparing and applying Hypericum perforatum-derived exosome-like nanovesicles (HPDENs). This invention prepares HPDENs with natural vesicle structures through a specific process, utilizing the natural characteristics of plant-derived vesicles to encapsulate Hypericum perforatum (…). HP The active ingredient, combined with nasal drops, achieves targeted delivery to the brain. It exerts its antidepressant effect by regulating microglia polarization imbalance and reshaping the "neuroimmune-synaptic" axis. This solves the core problems of traditional antidepressants, such as slow onset of action, poor treatment response, and large side effects. It can also improve the core pathological features of depression (neuritis, synaptic plasticity damage) and improve depressive-like behaviors, providing a brand-new option for the clinical treatment of depression.

Dosage forms, drug delivery systems, and methods related to dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The invention discloses an intelligent cell strain as well as a construction method and application thereof, belongs to the technical field of biology, and aims to solve the limitation of single-point static monitoring, strong equipment dependence or insufficient biological safety in the existing detection technology. The method comprises the following steps: constructing a response element PCMV-GRLBD-NES-TetR by using a truncated receptor GRLBD, inserting the response element PCMV-GRLBD-NES-TetR and a report element SB-PTCE-SEAP into a genome of a host fine HEK-293T cell, and selecting a monoclonal cell responding to glucocorticoid; wherein the report protein in the report element can also use other target proteins besides alkaline phosphatase (SEAP), including but not limited to tyrosinase (Tyrosinase) and red fluorescent protein (tdTomato). The cell strain can be used for developing high-throughput screening of targeted mental stress drug molecules, and material reserve is provided for development of anti-depression and anti-anxiety drugs.

This invention relates to the field of biomedicine, and particularly to the application of anti-VLA4 therapy in antidepressant treatment by inhibiting the migration of γδ T cells to the central nervous system. This invention utilizes anti-VLA4 antibody treatment to reduce the infiltration of γδ T cells into the meninges and brain parenchyma of mice, revealing that anti-VLA4 inhibition of peripheral T cell migration can block CUMS-induced depressive-like behaviors, providing a novel strategy for the treatment of depression.

The invention discloses a botulinum toxin type A heavy chain TD protein and application thereof. The amino acid sequence of the TD protein is as shown in SEQ ID No. 1, and the nucleotide sequence of the coding gene of the TD protein is as shown in SEQ ID No. 2. The botulinum toxin type A heavy chain TD protein is applied to preparation of anti-depression drugs, and is especially used for protecting neuronal functions and improving depression-like behaviors. The A-type botulinum toxin heavy chain TD protein effectively avoids the toxic effect of traditional A-type botulinum toxin, only effective fragments playing an anti-depression role in the A-type botulinum toxin heavy chain are extracted, and the effective anti-depression role is played by preparing small-molecule oligopeptide protein.